• 1
    Shroff R, Rees L. The post-transplant lymphoproliferative disorder—a literature review. Pediatr Nephrol. 2004; 19: 369-377.
  • 2
    Shapiro R, Nalesnik M, McCauley J, et al. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation. 1999; 68: 1851-1854.
  • 3
    Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation. 1988; 45: 719-727.
  • 4
    Leoncini L, Raphael M, Stein H, Harris NL, Jaffe ES, Kluin PM. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris N, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008: 262-264.
  • 5
    Vakiani E, Basso K, Klein U, et al. Genetic and phenotypic analysis of B-cell post-transplant lymphoproliferative disorders provides insights into disease biology. Hematol Oncol. 2008; 26: 199-211.
  • 6
    Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood. 1993; 82: 619-624.
  • 7
    Raphael M, Gentilhomme O, Tulliez M, Byron PA, Diebold J. Histopathologic features of high-grade nonHodgkin's lymphomas in acquired immunodeficiency syndrome. The French study group of pathology for human immunodeficiency virus-associated tumors. Arch Pathol Lab Med. 1991; 115: 15-20.
  • 8
    Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn. 2008; 10: 279-292.
  • 9
    Windebank K, Walwyn T, Kirk R, et al. Post cardiac transplantation lymphoproliferative disorder presenting as t(8;14) Burkitt leukaemia/lymphoma treated with low intensity chemotherapy and rituximab. Pediatr Blood Cancer. 2009; 53: 392-396.
  • 10
    Pasquale MA, Weppler D, Smith J, et al. Burkitt lymphoma variant of post-transplant lymphoproliferative disease (PTLD). Pathol Oncol Res. 2002; 8: 105-108.
  • 11
    Tweddle DA, Gennery AR, Reid MM, et al. Posttransplantation B lymphoblastic leukemia with Burkitt-like features. Transplantation. 1999; 67: 1379-1380.
  • 12
    Gong JZ, Stenzel TT, Bennett ER, et al. Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of 5 cases. Am J Surg Pathol. 2003; 27: 818-827.
  • 13
    Hunt BJ, Thomas JA, Burke M, Walker H, Yacoub M, Crawford DH. Epstein-Barr virus associated Burkitt lymphoma in a heart transplant recipient. Transplantation. 1996; 62: 869-872.
  • 14
    Riches J, Naresh K, Reid A, Macdonald D. Burkitt lymphoma following renal transplantation. Br J Haematol. 2009; 146: 583.
  • 15
    Johnson LR, Nalesnik MA, Swerdlow SH. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. Am J Surg Pathol. 2006; 30: 1604-1612.
  • 16
    Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of society for hematopathology workshop. Semin Diagn Pathol. 1997; 14: 8-14.
  • 17
    Lohrisch CA, Nevill TJ, Barnett MJ, et al. Development of a biologically distinct EBV-related lymphoproliferative disorder following autologous bone marrow transplantation for an EBV-negative post-renal allograft Burkitt's lymphoma. Leuk Lymphoma. 2000; 39: 195-201.
  • 18
    Chang KL, Chen YY, Shibata D, Weiss LM. Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol. 1992; 1: 246-255.
  • 19
    Aguilera NS, Kapadia SB, Nalesnik MA, Swerdlow SH. Extramedullary plasmacytoma of the head and neck: use of paraffin sections to assess clonality with in situ hybridization, growth fraction, and the presence of Epstein-Barr virus. Mod Pathol. 1995; 8: 503-508.
  • 20
    Dewald GW. Chapter 32. In: McClatchey KD, ed. Clinical Laboratory Medicine. 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2002: 11.
  • 21
    Wadowsky RM, Laus S, Green M, Webber SA, Rowe D. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol. 2003; 41: 5245-5249.
  • 22
    Hwang YY, Wong KY, Leung RY, et al. Post-rituximab Burkitt transformation of PTLD: loss of CD20 expression accompanied by a switch in light-chain expression. Ann Hematol. 2009; 89: 97-99.
  • 23
    Schauer E, Webber S, Kingsley L, Green M, Rowe D. Increased Ig-null B lymphocytes in the peripheral blood of pediatric solid organ transplant recipients with elevated Epstein-Barr viral loads. Pediatr Transplant. 2009; 13: 311-318.
  • 24
    Leucci E, Cocco M, Onnis A, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008; 216: 440-450.
  • 25
    Sevilla DW, Gong JZ, Goodman BK, et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007; 128: 981-991.
  • 26
    Shiramizu B, Barriga F, Neequaye J, et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood. 1991; 77: 1516-1526.
  • 27
    Metzelder M, Ure B. Port-site metastasis after laparoscopic biopsy of a posttransplant Burkitt lymphoma in a child. Eur J Pediatr Surg. 2009; 19: 126-127.
  • 28
    Cacciarelli TV, Reyes J, Jaffe R, et al. Primary tacrolimus (FK506) therapy and the long-term risk of post-transplant lymphoproliferative disease in pediatric liver transplant recipients. Pediatr Transplant. 2001; 5: 359-364.
  • 29
    Harris E, Paneesha S, Jackson N, Jones L, Mahendra P. Burkitt's lymphoma: single-centre experience with modified BFM protocol. Clin Lab Haematol. 2002; 24: 111-114.
  • 30
    Smets F, Vajro P, Cornu G, Reding R, Otte JB, Sokal E. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation. 2000; 69: 982-984.
  • 31
    Webber SA, Naftel DC, Fricker FJ, et al. Lymphoproliferative disorders after paediatric heart transplantation: a multi-institutional study. Lancet. 2006; 367: 233-239.
  • 32
    Dror Y, Greenberg M, Taylor G, et al. Lymphoproliferative disorders after organ transplantation in children. Transplantation. 1999; 67: 990-998.
  • 33
    Bingler MA, Feingold B, Miller SA, et al. Chronic high Epstein-Barr viral load state and risk for late-onset posttransplant lymphoproliferative disease/lymphoma in children. Am J Transplant. 2008; 8: 442-445.
  • 34
    Boccellato F, Anastasiadou E, Rosato P, et al. EBNA2 interferes with the germinal center phenotype by downregulating BCL6 and TCL1 in nonHodgkin's lymphoma cells. J Virol. 2007; 81: 2274-2282.
  • 35
    Capello D, Cerri M, Muti G, et al. Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood. 2003; 102: 3775-3785.